Scarica l'app Stockscreener
18.84
4.09%
0.74
Dopo l'orario di chiusura:
18.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$18.10
Aprire:
$17.452
Volume 24 ore:
1.94M
Relative Volume:
0.87
Capitalizzazione di mercato:
$3.11B
Reddito:
-
Utile/perdita netta:
$-446.21M
Rapporto P/E:
-5.3169
EPS:
-3.5434
Flusso di cassa netto:
$-423.92M
1 W Prestazione:
+1.56%
1M Prestazione:
+16.66%
6M Prestazione:
+50.12%
1 anno Prestazione:
+90.11%
Intervallo 1D:
$17.45
$18.90
Intervallo di 1 settimana:
$16.87
$19.02
Portata 52W:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.84 | 3.11B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed - Stock Titan
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders - Sahm
Dyne Therapeutics, Inc. (DYN) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Sahm
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) adds 2,000 common shares - Stock Titan
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Fed Watch: Can Dyne Therapeutics Inc disrupt its industryMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DYN Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Technical Reactions to DYN Trends in Macro Strategies - Stock Traders Daily
Is Dyne Therapeutics Inc a turnaround storyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Insider Monkey
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership - stocktitan.net
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
Raymond James reiterates Strong Buy on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co. - MarketBeat
Dyne Therapeutics (DYN) shares key details for pivotal drugs - MSN
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
Dyne Therapeutics (NASDAQ:DYN) Trading 4.4% HigherHere's Why - MarketBeat
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference - MarketBeat
Published on: 2026-03-19 20:58:12 - baoquankhu1.vn
Dyne Therapeutics details complex risk patterns and urgent care need for DM1 patients - Traders Union
Retail Trends: Is now the right time to enter Dyne Therapeutics IncOil Prices & Comprehensive Market Scan Insights - baoquankhu1.vn
Earnings Beat: Will Dyne Therapeutics Inc benefit from government policyWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Trading the Move, Not the Narrative: (DYN) Edition - Stock Traders Daily
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
MDA 2026: Dyne therapy boosts strength, cognition in DM1 - Muscular Dystrophy News
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN) - The Globe and Mail
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)? - simplywall.st
Why Dyne Therapeutics Stock Is Surging Higher Now - TipRanks
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case - simplywall.st
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
Integral Health Asset Management LLC Buys New Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Insider Sold Shares Worth $2,530,562, According to a Recent SEC Filing - marketscreener.com
Director buys 2,000 Dyne Therapeutics (DYN) shares in open market - Stock Titan
Fund tied to Dyne Therapeutics (DYN) director sells stock - Stock Titan
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Insider Monkey
WINTON GROUP Ltd Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data - simplywall.st
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria
688K Dyne Therapeutics (DYN) shares sold by ForDyne fund under 10b5-1 plan - Stock Titan
ForDyne B.V. (DYN) reports two Common stock dispositions on consecutive dates - Stock Titan
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (DYN), Biohaven Ltd. (BHVN) and Teladoc (TDOC) - The Globe and Mail
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade - Finviz
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):